Calico

Calico is the biotechnology company which is engaged in research and development for the purpose of fight against aging and diseases of the population. Calico founded in 2013 and entering into Alphabet holding by June, 2018 did not produce any medicine or a biotechnology product yet.

History

2018: Attraction of $1 billion investments

At the end of June, 2018 the Alphabet holding announced about $1 billion Calico investment. Means will be provided with assistance of the old partner of Calico — producer of AbbVie medicines. Thus, Calico from the moment of the basis received financing in total in the amount of $2.5 billion.

Within cooperation of AbbVie Calico with clinical trials helps and shares commercial experience. Calico specializes in research and development at early stages. The company is going to begin tests of the technologies on phase 2a after 2022 and to complete them to the 2027th.

Alphabet selects $1 billion for fight against aging

Since 2014 Calico and AbbVie developed more than 20 programs in the field of a neurobiology and oncology. Also the work devoted to new idea of aging biology was provided. Partners intend to halve profit on project implementation.

As notes CNBC TV channel, problems of aging are attractive area for the biotechnology companies which look for methods to facilitate problems with health which arise at aged people. The management on control of foodstuff and medicines of the USA (FDA) does not consider aging as a disease therefore some companies place emphasis on the diseases connected with an old age than on helping to save youth.^[1]

2014: Cooperation with AbbVie

In September, 2014 Calico announced partnership with biopharmaceutical company AbbVie. Within cooperation it was open R&D-центр, directed to problem solving of aging and age diseases, including cancer and neurodegenerative violations.

Then Google and AbbVie agreed to invest in Calico $350 million with a possibility of further additional investments in $1 billion.

Notes